Half-Year 2022 Financial and Clinical Trials Update
Major granted approvals 2022
US
EU
China
Vabysmo (faricimab)
RG7716
DME
Jan 2022
RG7596
Polivy
1L DLBCL
May 2022
RG7446
Tecentriq
NSCLC adj
March 2022
RG1569
Vabysmo (faricimab)
RG7716
WAMD
RG7446
Tecentriq
NSCLC adj
Actemra
RG1569
RA SC
RG7716
Japan-Chugai
Actemra
COVID-19 pneumonia
Jan 2022
Vabysmo (faricimab)
DME
Jan 2022
June 2022
April 2022
RG1569
RG7916
Actemra
GCA IV
Feb 2022
Evrysdi
SMA presymptomatic pediatric <2mo
May 2022
Lunsumio (mosunetuzumab)
March 2022
Vabysmo (faricimab)
RG7828
3L+FL
RG7716
WAMD
June 2022
March 2022
Perjeta + Herceptin
RG1273
HER-2+ CRC
New Molecular Entity (NME)
Additional Indication (AI)
Oncology/Hematology
Immunology
Infectious Diseases
Status as of July 21, 2022
Metabolism
Neuroscience
Ophthalmology
Other
RG7446
RG6013
RG105
March 2022
Tecentriq
NSCLC adj
May 2022
Hemlibra
acquired Hemophilia A
June 2022
Rituxan
NMOSD
June 2022
79
64
RocheView entire presentation